SPRINGER NATURE

Updated Q3 2026 - new indexing status and Impact Factors

A proven track record of fast and flexible publishing solutions

Our portfolio of more than ***30 journals*** provides you with a publishing opportunity for your important scientific articles.

Complete journal list inside

Adis

All **Adis** Journals Offer:

- **Timely publication** – all Adis journals offer swift publication timelines through our Adis Premier journals, Adis VIP service, and the Adis Rapid+ journals.
- **Pre-submission enquiry service** – our journal editors are able to provide expert pre-submission technical feedback on pre-submitted manuscripts to ensure you are targeting the most suitable journal for your work. Please contact adisjournals@springernature.com; your email will be responded to by a member of our team within 1-2 working days.
- **Peer-reviewed digital features** – articles can host a wide range of features to enhance their educational value. Features should be submitted with the manuscript. For any queries, please contact adisjournals@springernature.com, where your email will be responded to within 1-2 working days.
- **Plain language summaries** – articles can be accompanied by a plain language summary (PLS), providing a succinct overview of a manuscript, to assist readers who may not have an in-depth knowledge of the topic to understand the scientific content and overall implications. The PLS is peer reviewed alongside the manuscript.
- **Summary of Research Articles** – standalone summaries of a previously published article, written for an audience that is less specialised than that intended for the source article.
- **Podcasts/Vodcasts** – standalone audio articles, accompanied by a verbatim transcript, are published on the journal website and can also be hosted on key streaming platforms. They are peer reviewed, citable, and indexed on PubMed.
- **Summary points** – all articles are published with a summary box, summarizing the key data points.
- **Cascading options** – if a manuscript is considered unsuitable for the journal to which it has been submitted, either before or after peer review, it may be cascaded to sister titles within the Adis portfolio or to wider Springer Nature titles. Articles are cascaded only with the author's permission.
- **Option for open access publication** – all Adis journals offer the opportunity to publish open access.
- **High ethical standards** – Adis endorses the ICMJE/WAME/COPE guidelines for journal editors, and encourages all manuscripts reporting sponsored research to comply with Good Publication Practice (GPP2022).
- **Global reach** – all Adis journals have substantial readership in Europe/US/Asia/ROW and are available to healthcare professionals worldwide as part of the Springer Nature global content packages.
- **SharedIt** – all articles are included in the Springer Nature SharedIt content-sharing initiative. SharedIt provides a sharable link for each article that gives access to a view-only, full-text version for non-commercial personal use. Links can be shared anywhere, including via social media channels and on other highly-used sites, institutional repositories and authors' own websites, as well as on scholarly collaborative networks.
- **Article metrics** – highly visible metrics are available for every article on SpringerLink, including article accesses, Altmetric score and citations. Further metrics are available on request.
- **Social media** – we provide social media guidance to all authors to encourage them to post about their research, and many of our journal editors have a strong social media presence.

Publishing Within **Adis** Rapid+ Journals

- **Rapid peer review for all submissions** – we endeavour to peer review all manuscripts within 2 weeks. Accepted articles appear online within 3-4 weeks of acceptance.
- **Personalized service** – the journal team will style and submit a manuscript on behalf of the authors.
- **Inclusive** - we will consider all scientifically and ethically sound research for publication.

Please note that for any steps outside of our standard publication processes, such as multiple rounds of peer review or article proofs, or non-standard copyright requests, this may delay publication beyond these timelines. The rapid publication service provided for all manuscripts is supported by a Rapid Service Fee, payable on publication, which includes: our rapid publication timelines; our personal concierge service and author support; and other offerings such as extensive article metrics upon request. No fee is charged for rejected manuscripts. For the fully open access Rapid+ journals, this fee also covers the non-commercial open access license (CC-BY-NC). For Advances in Therapy, authors can choose to pay an additional £3090/€3990/$4990 to make their article open access (CC-BY-NC). Please see individual journal descriptions within this brochure for details of charges.

Publishing Within **Adis** Premier Journals

- **Timely, responsive peer review** – we endeavour to peer review all articles within 4-6 weeks. Articles appear online ~3 weeks from acceptance.
- **Publishing options** – Adis Premier journals offer several publishing options, either without author charges, or open access in our hybrid journals (using Springer Open Choice) or our fully open access journals.
- **VIP service** – 30 days from submission to publication:
  - Intended submission should be sent to the VIP team journalvip@adis.com
  - Submission to first decision in 15 days, 1 week for authors to respond to peer review comments, and 24-hour turnaround for other required author tasks
  - DOI can be assigned within 48 hours of the paper being accepted for publication
  - Accepted manuscript can be placed on Figshare prior to publication for earlier public availability
  - Personal VIP service support is provided from a dedicated journal editor at every step
  - An administrative fee applies to all papers published using the Adis VIP service
  - No charge for rejected manuscripts

Authors can make their article open access (CC-BY-NC) with payment of an article processing charge (APC). See individual journal descriptions within this brochure for details.

Adis Drug Reviews

Adis publishes definitive single-agent reviews providing readers with the most important and clinically relevant information on the properties of new and established drugs, across all therapeutic areas. Adis Drug Reviews are written by the scientific editorial staff of Springer Nature, and independently peer reviewed by international experts. Articles can be made free to access for readers via an Expanded Access Grant upon request. For queries, please contact us at adisjournals@springernature.com

- **Adis Drug Evaluations** provide a definitive review of the important pharmacological properties, clinical efficacy, and tolerability of an agent. They critically evaluate the most important data on new or established agents and define their clinical potential or most appropriate place in therapy.
- **AdisInsight Reports** briefly review the important pharmacological properties, clinical efficacy, and tolerability of a newly approved agent. These reports are based on drug profile information from AdisInsight (a Springer Nature database) and are published shortly after a drug receives approval in its first indication in any market.
- **Adis Drug Q&As** focus on the practical use of a drug in the clinical setting. Using a Q&A format, the article provides a succinct, evidence-based review of the pharmacological properties, efficacy, tolerability, and current clinical use of the drug.
- **Adis Biosimilar Briefs** focus on the important pharmacological properties (including preclinical characterization), clinical efficacy, and tolerability of a biosimilar in relation to the reference biologic agent.

Adis Journals

Journal	Title	Indexing*	Metrics**	Features	Description
	**Advances in Therapy**	Medline / PubMed Embase	I.F 4.7 CiteScore 7.6		Publishes high-quality clinical, observational (real-world), and HEOR studies in all therapeutic areas. Reviews, patient-reported outcomes, and other patient-involved content also welcomed. **Extensive Editorial Board including Section Editors: Ian Menown (cardiology), Aristidis Veves (diabetes), Chris Twelves (oncology), Roger McIntyre (psychiatry), and Rene Rizzoli (rheumatology)**. Mandatory Rapid Service Fee: £5600/€6500/$8385. Articles can be made open access for a fee of £3090/€3990/$4990.
	American Journal of Cardiovascular Drugs	Medline / PubMed Embase	I.F 3.2 CiteScore 6.0		Promotes rational therapy and effective patient management in cardiovascular medicine. Publishes reviews and original research articles covering all aspects of the management of cardiovascular disorders, particularly the place in therapy of newer and established drugs, devices, and other interventions. Official journal of the International Academy of Cardiovascular Sciences (IACS; www.heartacademy.org). **Editor-in-Chief: Amitabh Prakash**. Articles can be made open access for a fee of £3,090/€3,990/$4,990.
	American Journal of Clinical Dermatology	Medline / PubMed Embase	I.F 11.4 CiteScore 19.2		Promotes evidence-based therapy and effective patient management in dermatology. Publishes critical and comprehensive review articles and clinically focused original research articles covering all aspects of the management of dermatological conditions. **Editor-in-Chief: Christine Noble**. Articles can be made open access for a fee of £3890/€4590/$5790.
	Applied Health Economics & Health Policy	Medline / PubMed Embase	I.F 3.1 CiteScore 6.4		Publishes practical health economics and outcomes research, reviews and opinion, to inform real-world healthcare decisions. Covers all interventions, including devices, diagnostics and drugs, and health policy initiatives. Of high interest to payers, providers and other decision makers. **Editor-in-Chief: Tim Wrightson**. Articles can be made open access for a fee of £3190/€3990/$5190.
	BioDrugs	Medline / PubMed Embase	I.F 8.5 CiteScore 13.8		Publishes original research and reviews of the latest developments in the clinical application of biotechnology for the treatment of human disease, including aspects of target selection, drug development and delivery, and clinical use of biologics and molecularly targeted therapeutics. *R+ applies to original research articles only. **Editor-in-Chief: Mike Herbert**. For original research articles there is a mandatory Rapid Service Fee of £5120/€5950/$7675. Articles can be made open access for a fee of £3790/€4490/$5490.
	**Cardiology and Therapy**	PubMed Embase	I.F 3.2 CiteScore 5.5		Publishes clinical and observational (real-world) research, reviews, and case reports across the spectrum of the prevention and management of cardiovascular disease, including both pharmaceutical and interventional surgical and device therapies. HEOR studies also welcomed. **Editors-in-Chief: Anthony A. Bavry (USA), Uwe Zeymer (Europe), and Ian Menown (interventional)**. Mandatory Rapid Service Fee: £5120/€5950/$7675. All articles are published open access.

Adis Journals

Journal	Title	Indexing*	Metrics**	Features	Description
	Clinical Drug Investigation	Medline / PubMed Embase	I.F 3.1 CiteScore 5.2		Publishes original research and reviews covering all phases of clinical drug development and therapeutic use of drugs and drug devices, as well as pharmacoeconomic and outcomes research, across all therapeutic areas. **Editor-in-Chief: Sophie Stevenson**. Articles can be made open access for a fee of £2890/€3290/$4390.
	Clinical Pharmacokinetics	Medline / PubMed Embase	I.F 4.0 CiteScore 7.6		Promotes continuing development of clinical pharmacokinetics and pharmacodynamics to optimize drug therapy, and to further postgraduate education in clinical pharmacology and therapeutics. Publishes reviews and clinically-focussed original research articles. **Editors-in-Chief: Amitabh Prakash and Anton van Rensburg**. Articles can be made open access for a fee of £3190/€3990/$5190.
	CNS Drugs	Medline / PubMed Embase	I.F 7.0 CiteScore 13.7		Promotes rational pharmacotherapy and effective patient management within the disciplines of clinical psychiatry and neurology. Publishes reviews and original research articles covering important issues in the drug treatment of psychiatric and neurological disorders. **Editor-in-Chief: Sue Pochon**. Articles can be made open access for a fee of £3290/€4190/$5290.
	Dermatology and Therapy	PubMed Embase	I.F 4.6 CiteScore 7.3		Covers all clinical aspects of medical dermatology, including the prevention, diagnosis, and management of skin disorders and skin cancer; as well as esthetic dermatology, including skin maintenance and surgical procedures. Observational (real-world) research, reviews, HEOR, and case reports also welcomed. **Editors-in-Chief: Alan Menter (USA), Jennifer Hsiao (USA), Richard Warren (Europe), and Giovanni Damiani (Europe)**. Mandatory Rapid Service Fee: £5120/€5950/$7675. All articles are published open access.
	Diabetes Therapy	PubMed Embase	I.F 4.2 CiteScore 5.7		Focuses on cutting-edge clinical and observational (real-world) research in the prevention, treatment, management, and education of diabetes and related disorders, including obesity and metabolic syndromes as well as device-related therapies. Reviews, HEOR, and case reports also welcomed. **Editors-in-Chief: Fernando Ovalle (USA) and Marc Evans (Europe)**. Mandatory Rapid Service Fee: £5120/€5950/$7675. All articles are published open access.
	Drug Safety	Medline / PubMed Embase	I.F 5.9 CiteScore 8.4		Advances the rational use of pharmacotherapy by publishing reviews and original research articles offering guidance for safe and effective drug utilization and prescribing. Of high interest to healthcare professionals, regulators, and pharma industry personnel with an interest in drug safety, pharmacovigilance and pharmacoepidemiology. Drug Safety is the official journal of the International Society of Pharmacovigilance. **Editor-in-Chief: Nitin Joshi**. Articles can be made open access for a fee of £3190/€3990/$5190.

Adis Journals

Journal	Title	Indexing*	Metrics**	Features	Description
	Drugs	Medline / PubMed Embase	I.F 14.7 CiteScore 25.3		Promotes optimum pharmacotherapy by publishing reviews and original clinical research articles, covering the most important aspects of clinical pharmacology and therapeutics. Drugs also includes Adis Drug Evaluations and overviews of drugs receiving a first global approval (AdisInsight Reports). **Editor-in-Chief: Sue Pochon**. Articles can be made open access for a fee of £4190/€4990/$6290.
	Drugs & Aging	Medline / PubMed Embase	I.F 4.2 CiteScore 7.2		Promotes optimum drug therapy in older adults through reviews and original research articles covering the most important aspects of clinical pharmacology and patient management in this patient group. Physiological changes during aging that have implications for drug therapy also fall within the scope of the journal. The only Medline-indexed journal specifically dedicated to pharmacology in older adults. **Editor-in-Chief: Caroline Herdson**. Articles can be made open access for a fee of £3290/€4090/$5290.
	Drugs & Therapy Perspectives	PubMed application due 2026 Embase	I.F 0.6 CiteScore 1.0		Provides concise, authoritative guidance on the choice and clinical use of drugs for all healthcare professionals. The journal includes step-by-step patient care guidelines, overviews of drugs and their place in therapy, Q&As on the clinical use of drugs, current thinking on disease management, and other clinically relevant topics. Original research and reviews that focus on clinical practice are welcome. **Editors-in-Chief: Nitin Joshi and Anton van Rensburg**. Open access fee: £2490/€2890/$3590.
	Drugs in R&D	Medline / PubMed Embase	I.F 2.5 CiteScore 4.0		Publishes clinical research on both new and established drugs, and preclinical research of direct relevance to clinical drug development, in all therapeutic areas. Original research, reviews, and case reports are welcomed. **Editor-in-Chief: Anton van Rensburg**. Open access fee: £2290/€2690/$3390.
	**Drugs – Real World Outcomes**	PubMed Embase	I.F 2.0 CiteScore 3.9		Publishes research involving the use of real-world data to evaluate health outcomes and inform healthcare decision-making, with a particular focus on healthcare-related 'big data'. Has a broad scope, encompassing studies investigating drug utilization, patterns of prescribing, pharmacovigilance, treatment guideline adherence, benefit-risk assessments, comparative effectiveness, and economic analyses. **Editor-in-Chief: Sophie Stevenson**. Open access fee: £2390/€2690/$3190.

Adis Journals

Journal	Title	Indexing*	Metrics**	Features	Description
	**European Journal of Drug Metabolism and Pharmacokinetics**	Medline / PubMed Embase	I.F 2.3 CiteScore 4.9		Publishes original research and reviews addressing all aspects of preclinical and clinical pharmacokinetics, including drug disposition, drug metabolism, drug transport, drug interactions, bioavailability and biopharmacy, and pharmacokinetic modelling. **Editor-in-Chief: Anton van Rensburg**. Articles can be made open access for a fee of £2890/€3290/$4390.
	Infectious Diseases and Therapy	PubMed Embase	I.F 5.6 CiteScore 9.3		Publishes high-quality clinical assessments of drug therapies and interventions (including vaccines, diagnostics, and antimicrobial stewardship programs), as well as observational (real-world) and HEOR assessments. Reviews and case reports also welcomed. **Editors-in-Chief: Michael J. Rybak (USA) and Alex Soriano (Europe)**. Mandatory Rapid Service Fee: £5120/€5950/$7675. All articles are published open access.
	Molecular Diagnosis & Therapy	Medline / PubMed Embase	I.F 5.8 CiteScore 10.0		Publishes reviews and original research articles linking diagnostic and prognostic biomarkers to appropriate therapy, with an emphasis on the development of companion diagnostic/therapeutic products, along with the analysis of pharmacogenomic data for drug development and therapeutic decision-making. **Editor-in-Chief: Alison Fitches**. Articles can be made open access for a fee of £3290/€4190/$5290.
	**Neurology and Therapy**	PubMed Embase	I.F 4.7 CiteScore 7.9		Publishes original research, reviews, case reports, and commentaries on diagnosis and therapy for neurological and mental health indications, including devices and medical technologies. Accepts clinical, observational (real world), HEOR, quality of life, and patient-reported outcomes data. Patient-physician perspective articles are also welcomed. **Editors-in-Chief: Marwan Sabbagh (USA) and Antonio Bertolotto (Europe)**. Mandatory Rapid Service Fee: £5120/€5950/$7675. All articles are published open access.
	Oncology and Therapy	PubMed Embase	I.F 3.4 CiteScore 4.4		Publishes pre-clinical, clinical, observational (real-world) research and HEOR around the discovery, development and use of cancer therapies, including devices. Studies relating to diagnosis, public health, biomarkers, quality of life, patient-reported outcomes, and patient care, management and education are also encouraged. Reviews and case reports also welcomed. **Editor-in-Chief: Kenrick Ng (Europe)**. Mandatory Rapid Service Fee: £5120/€5950/$7675. All articles are published open access.

Adis Journals

Journal	Title	Indexing*	Metrics**	Features	Description
	**Ophthalmology and Therapy**	PubMed Embase	I.F 4.2 CiteScore 6.5		Publishes pre-clinical, clinical, observational (real-world), and HEOR studies around the discovery, development, and use of ophthalmological therapies, devices, and surgical techniques. Articles relating to diagnosis, public health, quality of life, patient care, management, and education are also encouraged. **Editors-in-Chief: Terrence P. O'Brien (USA) and Tariq Aslam (Europe)**. Mandatory Rapid Service Fee: £5120/€5950/$7675. All articles are published open access.
	Pain and Therapy	PubMed Embase	I.F 4.4 CiteScore 6.6		Focuses on all areas of pain therapy and pain-related devices . Research in all clinical phases, right through to observational (real-world) studies are welcomed, as well as HEOR, reviews, case reports, and studies relating to diagnosis, public health, quality of life, and patient care, management, and education. **Editors-in-Chief: Giustino Varrassi (Europe) and Andrea Trescot (USA)**. Mandatory Rapid Service Fee: £5120/€5950/$7675. All articles are published open access.
	Pediatric Drugs	Medline / PubMed Embase	I.F 3.7 CiteScore 7.0		Promotes the optimization and advancement of all aspects of pediatric pharmacotherapy (including vaccines) and clinical pharmacology. Timely reviews and original research articles provide healthcare decision-makers with clinically applicable knowledge on issues relevant to drug therapy in all areas of neonatology, and the care of children and adolescents. **Editor-in-Chief: Rod McNab**. Articles can be made open access for a fee of £3190/€3990/$5190.
	Pharmaceutical Medicine	Medline / PubMed Embase	I.F 4.7 CiteScore 8.4		Promotes the multidisciplinary specialty of pharmaceutical medicine, providing original research and reviews for professionals working in clinical drug development and related fields, encompassing medical aspects of the discovery, development, evaluation, registration, regulation, monitoring, marketing, distribution, and pricing of medicines, drug-device and drug-diagnostic combinations. **Editor-in-Chief: Sue Pochon**. Articles can be made open access for a fee of £3090/€3490/$4590.
	PharmacoEconomics	Medline / PubMed Embase	I.F 4.7 CiteScore 8.5		Provides a practical economic background to informed healthcare decision making. An essential resource for all clinicians and other professionals involved with healthcare resource allocation, budgeting and prescribing decisions. **Editors-in-Chief: Chris Carswell and Tim Wrightson**. Articles can be made open access for a fee of £3190/€3990/$5190.

Adis Journals

Journal	Title	Indexing*	Metrics**	Features	Description
	PharmacoEconomics – Open	PubMed Embase	I.F 2.4 CiteScore 4.3		Publishes applied research on the economic implications and health outcomes associated with drugs, devices, and other healthcare interventions. Focuses on original research and definitive reviews applying sound health economics and outcomes research methods to inform optimal healthcare policy and practice. **Editors-in-Chief: Chris Carswell and Tim Wrightson**. Open access fee: £2790/€3190/$4090.
	**Pulmonary Therapy**	PubMed Embase	I.F 3.4 CiteScore 4.9		Publishes research on all areas of pulmonary/respiratory medicine, from clinical research through to observational (real-world) studies, whether focused on a drug, device, or more general aspect of pulmonary medicine. Research, reviews, and case reports relating to diagnosis, HEOR, public health, quality of life, and patient care, management, and education are also encouraged. **Editors-in-Chief: Kai-Michael Beeh (Europe) and Rajiv Dhand (USA).** Mandatory Rapid Service Fee: £5120/€5950/$7675. All articles are published open access.
	**Rheumatology and Therapy**	PubMed Embase	I.F 3.1 CiteScore 5.9		Publishes research on all rheumatologic conditions, whether focused on a drug, device, or more general aspects of a disease. Welcomes research in all clinical phases, right through to observational (real-world) studies, as well as case reports and reviews relating to treatment, diagnosis, HEOR, public health, quality of life as well as patient care, management, and education. **Editor-in-Chief: Roy Fleischmann (USA)**. Mandatory Rapid Service Fee: £5120/€5950/$7675. All articles are published open access.
	Targeted Oncology	Medline / PubMed Embase	I.F 5.1 CiteScore 6.9		Focuses on original research articles on both preclinical and clinical aspects of molecularly targeted agents, and on comprehensive narrative review articles discussing clinically established as well as emerging agents and pathways. This journal is a pragmatic tool for all physicians and scientists committed to oncology and cancer research. **Editor-in-Chief: Martin Chopra**. Articles can be made open access for a fee of £3190/€3990/$5190.
	The Patient: Patient-Centered Outcomes Research	Medline / PubMed Embase	I.F 4.4 CiteScore 5.8		Focuses on the publication of patient reported outcomes and patient preference research in order to inform patient centered clinical decision making. An Official Journal of the International Academy of Health Preference Research (IAPHR; www.iaphr.org). **Editor-in-Chief: Chris Carswell**. Articles can be made open access for a fee of £3190/€3990/$5190.

Journal Key

Feature	Description
Open Choice	**Springer's Open Choice program** allows authors to publish open access in the Adis hybrid journals. Open Choice articles are freely available online immediately upon publication and clearly labelled on SpringerLink using an open access button, with authors retaining non-commercial copyright (through the CC-BY-NC licence). An open access fee is charged – please see individual journal descriptions within the brochure for details of fees.
Open Access	**Fully open access journal** with unrestricted online access. Authors retain non-commercial copyright to their work (through the CC-BY-NC licence). Please see individual journal descriptions within this brochure for details of fees.
Adis Drug Reviews	Publishes definitive **Adis-authored reviews** of both newer and established drugs and their place in disease management.
Q1	Journal ranked in the **first quartile** of the relevant Clarivate Analytics category.
Q2	Journal ranked in the **second quartile** of the relevant Clarivate Analytics category.
P	**Adis** Premier journals
R+	**Adis** Rapid+ journals

Open access publishing in any Adis journal allows articles to comply with open access mandates, including re-use and immediate deposit of the final article version in any repository. **Prices quoted in this brochure are current at the time of printing.** Also published by the Adis imprint: *High Blood Pressure & Cardiovascular Prevention*, and *Reactions Weekly*. Please see https://link.springer.com/journal/40292 and https://link.springer.com/journal/40278 for more details on these titles.
*Adis journals are also included in a wide range of other abstracting/indexing services. See journal website for details;
**Clarivate Analytics 2025 Impact Factor and 2025 CiteScore™ unless otherwise stated. Information updated June 2026.

Publishing with **Adis**

Adis Premier journals

Peer review 4–6 weeks	Author revisions	Acceptance to publication ~3 weeks

Adis VIP service

A bespoke "30 days from submission to publication" service offered by the Adis Premier journals.

Submission to first decision 15 days	Author revisions 7 days	Acceptance to publication 8 days

Adis Rapid+ journals

Peer review 2 weeks	Author revisions	Acceptance to publication 3–4 weeks

We strongly recommend using our pre-submission enquiry service to help you achieve your publication goals. Please contact adisjournals@springernature.com; your email will be responded to by a member of the team within 1-2 working days.

© 2026 Springer Nature. All rights reserved.

Find out more

If you would like to find out more about publishing with Adis, visit **adis.com** or contact one of our publishing team:

Clare Cook

Adis Editorial Manager
clare.cook@springernature.com

Lydia Alborn

Editor
lydia.alborn@springer.com

Kathryn McLaughlin

Editorial Assistant
kathryn.mclaughlin@springernature.com

Michael Mason

Associate Editor
michael.mason@springer.com

You can also direct any queries to adisjournals@springernature.com, where your email will be directed to the most appropriate person and will be responded to within 1-2 working days.

SPRINGER NATURE

Springer nature portfolio BMC palgrave macmillan Discover SCIENTIFIC AMERICAN Adis

SPRINGER NATURE

adis.com

Adis